Legend Biotech Corporation has announced that it will present preliminary Phase 1 clinical data for its investigational LB2501 therapy during a late-breaking oral session at the European Hematology Association Congress in Stockholm, focusing on patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

• Therapy profile: LB2501 is an investigational CD19/CD20 dual-target in vivo CAR-T cell therapy designed to generate CAR-T cells directly within the patient using a lentiviral vector platform.
• Clinical trial scope: Data are from an ongoing open-label Phase 1 study involving 12 patients across two dose levels as of 1 April 2026.
• Safety and efficacy findings: At dose level 2, an objective response rate of 100% (6/6) and complete response rate of 83.3% (5/6) were reported, with no dose-limiting toxicities, serious adverse events or deaths observed.

This summary is based on a press release issued by Legend Biotech.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.